VIRAL DEFECTIVE VACCINE PRODUCED BY TRANSCOMPLEMENTING CELL LINE
Patent Number: GB2263480
Publication date: 1993-07-28
Inventor(s): BOURSNELL MICHAEL EDWARD;; INGLIS STEPHEN CHARLES;; MINSON ANTHONY CHARLES
Applicant(s): CANTAB PHARMA RES (GB)
Requested Patent: HK1001656
Application Number: GB19930006044 19930323
Priority Number(s): GB19900020799 19900925; WO1991GB01632 19910923; GB19910004903 19910308
IPC Classification: A61K39/21; A61K39/395; C12N7/01; C12N7/04; C12N15/86
EC Classification: C12N15/86D, C12N15/86D1, C07K14/155
Equivalents: AU658836, AU8648991, BR9106879, CA2091678, DE69132311D, DE69132311T, EP0550553 (WO9205263), B1, ES2150416T, FI110438B, FI931309, JP6504194T, MX9203717, OA9777, WO9205263
------------------------------------------------------------------------
Abstract
------------------------------------------------------------------------
A mutant virus for use as a vaccine, wherein the genome of the virus is defective in respect of a gene essential for the production of infectious virus. In one aspect the mutant virus is capable of protecting a susceptible species immunized therewith against infection by the corresponding wild-type virus. In another aspect, the mutant virus acts as a vector for an immunogenic protein derived from a pathogen and which is encoded by foreign DNA incorporated in the mutant virus. The mutant virus can be produced in a recombinant host cell which expresses a gene complementing the defect. The mutant virus is preferably infectious for the host to be protected, but the defective gene allows expression in the infected host of at least some of the viral genes, which can provoke a cell-mediated immune response. |
